H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 101 Citations 36,863 504 World Ranking 3650 National Ranking 42

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Diabetes mellitus
  • Endocrinology

His primary areas of study are Internal medicine, Endocrinology, Diabetes mellitus, Insulin and Type 2 diabetes. In his work, Exenatide and Randomized controlled trial is strongly intertwined with Liraglutide, which is a subfield of Internal medicine. His works in Glucagon-like peptide-1, Glucagon, Incretin, Postprandial and Insulin resistance are all subjects of inquiry into Endocrinology.

He has included themes like Gastrointestinal hormone and Glucagon secretion in his Glucagon-like peptide-1 study. His work carried out in the field of Diabetes mellitus brings together such families of science as Gastroenterology and Carbohydrate metabolism. He combines subjects such as Basal, Glucose tolerance test, Glucose clamp technique and Skeletal muscle with his study of Type 2 diabetes.

His most cited work include:

  • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study (1213 citations)
  • Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients (792 citations)
  • Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. (739 citations)

What are the main themes of his work throughout his whole career to date?

Sten Madsbad focuses on Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Type 2 diabetes. While the research belongs to areas of Internal medicine, he spends his time largely on the problem of Glucagon-like peptide-1, intersecting his research to questions surrounding Gastric emptying. Incretin, Pancreatic hormone, C-peptide, Carbohydrate metabolism and Liraglutide are among the areas of Endocrinology where the researcher is concentrating his efforts.

His study in Insulin is interdisciplinary in nature, drawing from both Hormone and Type 1 diabetes. His work in Diabetes mellitus addresses subjects such as Gastric bypass surgery, which are connected to disciplines such as Roux-en-Y anastomosis. His Type 2 diabetes research includes elements of Metformin, Body mass index, Surgery, Gastroenterology and Type 2 Diabetes Mellitus.

He most often published in these fields:

  • Internal medicine (94.06%)
  • Endocrinology (77.53%)
  • Insulin (47.51%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (94.06%)
  • Endocrinology (77.53%)
  • Diabetes mellitus (42.22%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Insulin. His research in Internal medicine intersects with topics in Gastroenterology and Liraglutide. His work on Hormone, Carbohydrate metabolism and Glucagon-like peptide-1 as part of general Endocrinology study is frequently linked to Peptide YY, therefore connecting diverse disciplines of science.

His Diabetes mellitus research incorporates themes from Relative risk, Confidence interval and Gastric bypass surgery. In Type 2 diabetes, Sten Madsbad works on issues like Metformin, which are connected to Adverse effect. His Insulin study which covers Type 1 diabetes that intersects with Bolus.

Between 2017 and 2021, his most popular works were:

  • Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. (60 citations)
  • Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial (58 citations)
  • Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. (47 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Diabetes mellitus
  • Type 2 diabetes

His scientific interests lie mostly in Internal medicine, Endocrinology, Type 2 diabetes, Postprandial and Diabetes mellitus. His research integrates issues of Gastroenterology and Liraglutide in his study of Internal medicine. His study in the field of Glucagon, Insulin resistance, Small intestine and NEFA is also linked to topics like Context.

His work deals with themes such as Glucagon-like peptide-1, Appetite and Weight loss, which intersect with Postprandial. In his papers, Sten Madsbad integrates diverse fields, such as Diabetes mellitus and Crossover study. His Insulin research integrates issues from Type 1 diabetes and Carbohydrate.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander;Mette Zander;Sten Madsbad;Jan Lysgaard Madsen;Jens Juul Holst.
The Lancet (2002)

1624 Citations

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

Mai-Britt Toft-Nielsen;Mette B. Damholt;Sten Madsbad;Linda M. Hilsted.
The Journal of Clinical Endocrinology and Metabolism (2001)

1108 Citations

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll;Thure Krarup;Carolyn F. Deacon;Sten Madsbad.
Diabetes (2001)

1084 Citations

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Anthony H. Barnett;Stephen C. Bain;Paul Bouter;Bengt Karlberg.
The New England Journal of Medicine (2004)

911 Citations

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll;Milan Zdravkovic;Tu Le-Thi;Thure Krarup.
Diabetes Care (2007)

664 Citations

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on β-Cell Sensitivity in Type 2 and Nondiabetic Subjects

Lise L. Kjems;Jens J. Holst;Aage Vølund;Sten Madsbad.
Diabetes (2003)

635 Citations

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Tina Vilsbøll;T Krarup;J Sonne;S Madsbad.
The Journal of Clinical Endocrinology and Metabolism (2003)

604 Citations

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Tina Vilsbøll;T Krarup;S Madsbad;Jens Møller Holst.
Diabetologia (2002)

583 Citations

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Sten Madsbad;Ole Schmitz;Jonas Ranstam;Grethe Jakobsen.
Diabetes Care (2004)

457 Citations

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Tina Vilsbøll;Thure Krarup;Sten Madsbad;Jens Juul Holst.
Regulatory Peptides (2003)

455 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Sten Madsbad

Jens J. Holst

Jens J. Holst

University of Copenhagen

Publications: 567

Filip K. Knop

Filip K. Knop

University of Copenhagen

Publications: 198

Carolyn F. Deacon

Carolyn F. Deacon

University of Copenhagen

Publications: 145

Michael Horowitz

Michael Horowitz

University of Adelaide

Publications: 124

Daniel J. Drucker

Daniel J. Drucker

Lunenfeld-Tanenbaum Research Institute

Publications: 105

Bo Ahrén

Bo Ahrén

Lund University

Publications: 102

Allan Vaag

Allan Vaag

Steno Diabetes Center

Publications: 100

Michael A. Nauck

Michael A. Nauck

Ruhr University Bochum

Publications: 99

Torben Hansen

Torben Hansen

University of Copenhagen

Publications: 95

Oluf Pedersen

Oluf Pedersen

University of Copenhagen

Publications: 94

Peter R. Flatt

Peter R. Flatt

University of Ulster

Publications: 88

Karen L. Jones

Karen L. Jones

University of Adelaide

Publications: 86

Leif Groop

Leif Groop

Lund University

Publications: 86

Juris J. Meier

Juris J. Meier

Ruhr University Bochum

Publications: 78

David A. D'Alessio

David A. D'Alessio

Duke University

Publications: 77

Something went wrong. Please try again later.